Login to Your Account

Biolinerx Teams with Jiangsu for Hepatitis C Drug in China

By Shannon Ellis
Contributing Writer

Friday, June 14, 2013

SHANGHAI, China – A licensing agreement may help troubled Israeli Biolinerx Ltd. get a toehold in China with its HCV treatment BL-8030. In a deal worth as much as $30 million in initial and milestone payments, Biolinerx entered an agreement for the development, manufacture and commercialization of BL-8030 with liver therapy specialist Jiangsu Chia-tai Tianqing Pharmaceutical Co. Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription